MenACWY-TT long-term persistence and booster study in toddlers previously primed in study 109670

Phase 3, open-label trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine and Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease (2 arms), sponsored by GSK. Primary endpoints: Persistence of immunogenicity at 24 months post primary dose, Persistence of immunogenicity at 36 months post primary dose and 1 more. Started Jun 2009; status: completed.